Dosing and Safety Profile of Aficamten in Symptomatic Obstructive Hypertrophic Cardiomyopathy: Results From SEQUOIA-HCM

Caroline J Coats*, Ahmad Masri, Michael E Nassif, Roberto Barriales-Villa, Michael Arad, Nuno Cardim, Lubna Choudhury, Brian Claggett, Hans-Dirk Düngen, Pablo Garcia-Pavia, Albert A Hagège, James L Januzzi, Matthew M Y Lee, Gregory D Lewis, Chang-Sheng Ma, Martin S Maron, Zi Michael Miao, Michelle Michels, Iacopo Olivotto, Artur OreziakAnjali T Owens, John A Spertus, Scott D Solomon, Jacob Tfelt-Hansen, Marion van Sinttruije, Josef Veselka, Hugh Watkins, Daniel L Jacoby, Polina German, Stephen B Heitner, Stuart Kupfer, Justin D Lutz, Fady I Malik, Lisa Meng, Amy Wohltman, Theodore P Abraham, SEQUOIA‐HCM Investigators *

*Corresponding author for this work
1 Citation (Scopus)

Abstract

BACKGROUND: Aficamten, a novel cardiac myosin inhibitor, reversibly reduces cardiac hypercontractility in obstructive hypertrophic cardiomyopathy. We present a prespecified analysis of the pharmacokinetics, pharmacodynamics, and safety of aficamten in SEQUOIA-HCM (Safety, Efficacy, and Quantitative Understanding of Obstruction Impact of Aficamten in HCM).

METHODS AND RESULTS: A total of 282 patients with obstructive hypertrophic cardiomyopathy were randomized 1:1 to daily aficamten (5-20 mg) or placebo between February 1, 2022, and May 15, 2023. Aficamten dosing targeted the lowest effective dose for achieving site-interpreted Valsalva left ventricular outflow tract gradient <30 mm Hg with left ventricular ejection fraction (LVEF) ≥50%. End points were evaluated during titration (day 1 to week 8), maintenance (weeks 8-24), and washout (weeks 24-28), and included major adverse cardiac events, new-onset atrial fibrillation, implantable cardioverter-defibrillator discharges, LVEF <50%, and treatment-emergent adverse events. At week 8, 3.6%, 12.9%, 35%, and 48.6% of patients achieved 5-, 10-, 15-, and 20-mg doses, respectively. Baseline characteristics were similar across groups. Aficamten concentration increased by dose and remained stable during maintenance. During the treatment period, LVEF decreased by -0.9% (95% CI, -1.3 to -0.6) per 100 ng/mL aficamten exposure. Seven (4.9%) patients taking aficamten underwent per-protocol dose reduction for site-interpreted LVEF <50%. There were no treatment interruptions or heart failure worsening for LVEF <50%. No major adverse cardiovascular events were associated with aficamten, and treatment-emergent adverse events were similar between treatment groups, including atrial fibrillation.

CONCLUSIONS: A site-based dosing algorithm targeting the lowest effective aficamten dose reduced left ventricular outflow tract gradient with a favorable safety profile throughout SEQUOIA-HCM.

REGISTRATION: URL: https://www.clinicaltrials.gov; Unique Identifier: NCT05186818.

Original languageEnglish
JournalJournal of the American Heart Association
Volume13
Issue number15
Pages (from-to)e035993
ISSN2047-9980
DOIs
Publication statusPublished - 6 Aug 2024

Keywords

  • Adult
  • Aged
  • Atrial Fibrillation/drug therapy
  • Benzylamines
  • Cardiomyopathy, Hypertrophic/physiopathology
  • Dose-Response Relationship, Drug
  • Double-Blind Method
  • Female
  • Humans
  • Male
  • Middle Aged
  • Stroke Volume/drug effects
  • Treatment Outcome
  • Uracil/analogs & derivatives
  • Ventricular Function, Left/drug effects
  • cardiac myosin inhibitor
  • hypertrophic cardiomyopathy
  • aficamten

Fingerprint

Dive into the research topics of 'Dosing and Safety Profile of Aficamten in Symptomatic Obstructive Hypertrophic Cardiomyopathy: Results From SEQUOIA-HCM'. Together they form a unique fingerprint.

Cite this